Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AMG 139 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Part B | EXPERIMENTAL | One dose level of AMG 139 administered as a multiple doses IV in subjects with mild-severe Crohn's disease. |
| Part A | EXPERIMENTAL | Three dose levels of AMG 139 administered as a multiple doses IV or SC in healthy subjects. |
| Name | Type | Description |
|---|---|---|
| AMG 139 | DRUG | Four dose levels of AMG 139 administered as multiple doses IV or SC in healthy volunteers (Part A) and subjects with moderate-severe Crohn's disease (Part B). |
Inclusion Criteria: Part A - Healthy Subjects: * Healthy male or female of non-reproductive potential subjects between 18 to 45 years-of-age * Body mass index (BMI) between 18 and 32 kg/m2 * Normal or clinically acceptable physical examination, clinical laboratory values, and ECG * Additional incl...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 6 | PHASE3 | Duvakitug |
| Eli Lilly and Company | LLY | 8 | PHASE3 | Mirikizumab |
| AbbVie, Inc. | ABBV | 14 | PHASE3 | Risankizumab, Risankizumab On-Body Injector |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 16 | PHASE3 | Vedolizumab |
| Johnson & Johnson | JNJ | 13 | PHASE3 | Ustekinumab |
| Merck & Co., Inc. | MRK | 2 | PHASE3 | Tulisokibart |
| AstraZeneca PLC | AZN | 2 | PHASE2 | AZD7798 |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY001, SPY002, SPY003 |
| Abivax SA Sponsored ADR | ABVX | 1 | PHASE2 | Obefazimod |
| Palisade Bio, Inc. | PALI | 1 | PHASE1 | PALI-2108 |
| Novartis AG Sponsored ADR | NVS | 1 | - | Undisclosed |
| Amgen Inc. | AMGN | 1 | N/A | Undisclosed |
| TScan Therapeutics, Inc. | TCRX | 1 | - | Undisclosed |
AMG 139 is an investigational small molecule being studied for the treatment of Crohn's Disease and Psoriasis. It is in Phase 1 clinical development and is not approved by the FDA. The drug is being evaluated for safety, tolerability, pharmacokinetics, and pharmacodynamics in clinical trials.
AMG 139 is being developed by AstraZeneca PLC, which trades under the ticker symbol AZN. The drug is currently in Phase 1 clinical development for gastrointestinal and dermatological indications.
AMG 139 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials have been completed to evaluate its safety and tolerability in healthy subjects and patients with psoriasis or Crohn's disease.
AMG 139 has been studied in two completed Phase 1 clinical trials. NCT01094093 evaluated safety and tolerability in healthy subjects and subjects with moderate to severe psoriasis. NCT01258205 evaluated multiple ascending doses in healthy subjects and subjects with Crohn's disease.
AMG 139 is also known by its code name AMG 139. No other alternative names have been reported for this investigational drug. It is being developed by AstraZeneca for potential use in Crohn's disease and psoriasis.